Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
Status:
Completed
Trial end date:
2017-12-14
Target enrollment:
Participant gender:
Summary
Mantle cell lymphoma (MCL) is a sub-type of non-Hodgkin's lymphoma (NHL) which is generally
considered incurable with current therapy. Participants will receive an autologous vaccine
against their individual lymphoma after undergoing stem cell transplantation. This
vaccination may prolong the time which patients will stay in remission from their disease.